Trial Profile

A Pilot/Phase 1b Study of Glasdegib-Based Treatment Combinations in Adult Patients With Relapsed AML Post Allogeneic Hematopoietic Cell Transplantation

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bosutinib (Primary) ; Decitabine (Primary) ; Enasidenib (Primary) ; Gilteritinib (Primary) ; Glasdegib (Primary) ; Ivosidenib (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Jun 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
07 Mar 2022 Planned initiation date changed from 25 Dec 2021 to 25 Jun 2022.
29 Nov 2021 Planned initiation date changed from 25 Oct 2021 to 25 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com